Eventone Fade Cream, Regular

These describe what an ingredient is, not whether it is a problem. The stance marks above are the ratings; these are not.

• comedogenic in testingISOPROPYL MYRISTATE

  • ISOPROPYL MYRISTATE: A light emollient, and the ester the rabbit-ear literature names first. Fulton JE Jr, Pay SR, Fulton JE 3rd, "Comedogenicity of current therapeutic products, cosmetics, and ingredients in the rabbit ear", J Am Acad Dermatol 1984;10(1):96-105, PMID 6229554. The openly readable abstract names this ingredient among its "ingredient offenders", in prose and without a numeric rating: "Ingredient offenders include isopropyl myristate and its analogs, such as isopropyl palmitate, isopropyl isostearate, butyl stearate, isostearyl neopentanoate, myristyl myristate..." The rabbit-ear assay rates raw ingredients and does not predict how a finished formula behaves on human skin.

• common irritantPROPYLENE GLYCOL, SODIUM LAURYL SULFATE

  • PROPYLENE GLYCOL: A solvent that shows up in patch-test clinics, more often as irritation than as allergy. American Contact Dermatitis Society, Allergen of the Year 2018 (Jacob SE, Scheman A, McGowan MA, Dermatitis 2018;29(1):3-5).
  • SODIUM LAURYL SULFATE: A strong cleansing agent used as the reference irritant in skin-irritation testing. OECD Test Guideline 439 (in vitro skin irritation, reconstructed human epidermis), paragraph 24: "The suggested PC is 5% aqueous SDS", sodium dodecyl sulphate, the same substance as sodium lauryl sulfate, CAS 151-21-3.

• fragrance materialCITRONELLOL, HYDROXYCITRONELLAL, BUTYLPHENYL METHYLPROPIONAL, LINALOOL, LIMONENE

  • CITRONELLOL: A rose-and-citrus fragrance component named separately on the label. EU Regulation (EC) 1223/2009, Annex III entry 86: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products, because of established contact-allergy risk.
  • HYDROXYCITRONELLAL: A lily-like fragrance component named separately on the label. EU Regulation (EC) 1223/2009, Annex III entry 72: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products, because of established contact-allergy risk.
  • BUTYLPHENYL METHYLPROPIONAL: A lily-of-the-valley fragrance component the EU no longer permits in cosmetics. It was a declarable fragrance allergen at Annex III entry 83 of EU Regulation (EC) 1223/2009. Commission Regulation (EU) 2021/1902 deleted that entry and moved it to Annex II entry 1666 (2-(4-tert-butylbenzyl) propionaldehyde, CAS 80-54-6), prohibiting it in cosmetic products from 1 March 2022.
  • LINALOOL: A floral fragrance component named separately on the label. EU Regulation (EC) 1223/2009, Annex III entry 84: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products, because of established contact-allergy risk.
  • LIMONENE: A citrus-smelling fragrance component named separately on the label; the one name covers three related isomers. EU Regulation (EC) 1223/2009, Annex III entry 88: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products, because of established contact-allergy risk. That entry carries transition footnote (37): stock that does not comply, lawfully placed on the Union market before the 31 July 2026 cut-off, may still be made available until 31 July 2028. It is marked on the racemic dl-limonene/Dipentene line and the (S)-(l-limonene) line, but NOT the (R)-p-mentha-1,8-diene (d-limonene) line, CAS 5989-27-5, whose duty was already running as entry 88 before Commission Regulation (EU) 2023/1545 and so needed no transition. All three isomers are declared under the single glossary name "Limonene", so that name on a label does not identify which of them is present.

• undeclared fragrance blendFRAGRANCE

  • FRAGRANCE: A blend the label does not itemize, so what is in it cannot be read from the ingredient list. EU Regulation (EC) 1223/2009 permits the collective term "parfum"; the SCCS Opinion on Fragrance Allergens (SCCS/1459/11) reviews the contact-allergy evidence for the substances it can contain.

• retinoidRETINOL

  • RETINOL: A vitamin A derivative that speeds skin turnover; dryness and flaking while skin adjusts are its usual accompaniment. SCCS Opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate), SCCS/1576/16, final version of 6 October 2016; Commission Regulation (EU) 2024/996 added the group to EU Regulation (EC) 1223/2009 Annex III entry 376, capping it at 0,05% retinol equivalent in body lotion and 0,3% in other leave-on and rinse-off products, with the label statement "Contains Vitamin A. Consider your daily intake before use."

• rich occlusiveMINERAL OIL, DIMETHICONE

  • MINERAL OIL: A refined oil that sits on the surface of the skin; it has a heavy finish. FDA OTC skin protectant monograph, 21 CFR 347.10(l): "Mineral oil, 50 to 100 percent; 30 to 35 percent in combination with colloidal oatmeal in accordance with 347.20(a)(4)."
  • DIMETHICONE: A silicone that forms a film on the surface of the skin without an oily feel. FDA OTC skin protectant monograph, 21 CFR 347.10(g), lists dimethicone as a skin protectant at 1 to 30%.

• soothingNIACINAMIDE

  • NIACINAMIDE: A vitamin B3 form that supports the skin barrier and has anti-inflammatory activity; it turns up in products aimed at acne, rosacea and eczema. Camillo L, Zavattaro E, Savoia P, "Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond", Medicina (Kaunas) 2025;61(2):254, DOI 10.3390/medicina61020254, PMID 40005371, open access: it "is extensively used in ... the treatment of dermatological conditions such as blistering diseases, atopic dermatitis, rosacea, and acne vulgaris", and contributes to reducing inflammation. On the acne evidence specifically: Liu H, Yu H, Xia J, Liu L, Liu GJ, Sang H, Peinemann F, "Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne", Cochrane Database Syst Rev 2020;5:CD011368, DOI 10.1002/14651858.CD011368.pub2, PMID 32356369, records "low-quality evidence" for every nicotinamide comparison it could pool, and none of its four nicotinamide studies measured the physician global assessment at all.